Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference
Sensei Biotherapeutics (Nasdaq: SNSE) announced its participation in Citi's 2024 Global Healthcare Conference. The conference will take place from December 3-5 in Miami, FL. As a clinical stage biotechnology company specializing in next-generation cancer therapeutics, Sensei's management team will be present at this significant healthcare industry event.
Sensei Biotherapeutics (Nasdaq: SNSE) ha annunciato la sua partecipazione alla Conferenza Globale sulla Salute 2024 di Citi. La conferenza si terrà dal 3 al 5 dicembre a Miami, FL. Come azienda biotecnologica in fase clinica specializzata in terapie per il cancro di nuova generazione, il team di gestione di Sensei sarà presente a questo importante evento del settore sanitario.
Sensei Biotherapeutics (Nasdaq: SNSE) anunció su participación en la Conferencia Global de Salud 2024 de Citi. La conferencia se llevará a cabo del 3 al 5 de diciembre en Miami, FL. Como una empresa biotecnológica en etapa clínica especializada en terapias contra el cáncer de nueva generación, el equipo directivo de Sensei estará presente en este importante evento de la industria de la salud.
센세이 바이오테라퓨틱스 (Nasdaq: SNSE)는 씨티의 2024 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 이 컨퍼런스는 12월 3일부터 5일까지 플로리다주 마이애미에서 개최됩니다. 차세대 암 치료제에 전문화된 임상 단계 생명공학 회사로서, 센세이 경영진은 이 중요한 의료 산업 행사에 참석할 것입니다.
Sensei Biotherapeutics (Nasdaq: SNSE) a annoncé sa participation à la Conférence Mondiale sur la Santé 2024 de Citi. La conférence se déroulera du 3 au 5 décembre à Miami, en Floride. En tant qu'entreprise de biotechnologie en phase clinique spécialisée dans les thérapies contre le cancer de nouvelle génération, l'équipe de direction de Sensei sera présente à cet événement important de l'industrie de la santé.
Sensei Biotherapeutics (Nasdaq: SNSE) kündigte seine Teilnahme an der Citi's Global Healthcare Conference 2024 an. Die Konferenz findet vom 3. bis 5. Dezember in Miami, FL statt. Als ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf innovative Therapien gegen Krebs spezialisiert hat, wird das Management-Team von Sensei an diesem bedeutenden Event der Gesundheitsbranche teilnehmen.
- None.
- None.
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in Citi’s 2024 Global Healthcare Conference, being held on December 3-5, in Miami, FL.
About Sensei Biotherapeutics
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead product candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. For more information, please visit www.senseibio.com, and follow the company on X @SenseiBio and LinkedIn.
Investor Contact:
Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
mbiega@senseibio.com
Media Contact:
Joyce Allaire
LifeSci Advisors
Jallaire@lifesciadvisors.com
FAQ
When is Sensei Biotherapeutics (SNSE) participating in Citi's 2024 Global Healthcare Conference?
Where will Citi's 2024 Global Healthcare Conference featuring Sensei Biotherapeutics (SNSE) be held?
What is Sensei Biotherapeutics' (SNSE) main focus as presented at the Citi Healthcare Conference?
Which stock exchange is Sensei Biotherapeutics (SNSE) listed on?
